Diagnostics firm Randox is set to expand into the fertility industry - adding a dimension to its portfolio.
The fertility checks for both men and women involve in-depth physical and biological assessments, with 110 tests carried out, including Randox’s DNA-based protein testing, run on biochip array technology, which allows for simultaneous testing of multianalytes.
Randox managing director Peter FitzGerald said: “Around one in six couples in the UK has difficulty conceiving - due to our research and experience, we know that this is not always down to a problem with the sperm, eggs and reproductive organs. Issues in other parts of the body may have a significant impact on fertility, from hormone imbalance, obesity and stress.
“We are using the latest medical and scientific techniques available to assess the whole body, to provide clarity and to help boost fertility. For many couples, we know that very sophisticated treatment, such as IVF is not always needed. Sometimes even a simple change in lifestyle or diet is enough.”
The fertility health checks are being launched through Randox’s healthcare division Randox Health, in partnership with local fertility experts from GCRM Belfast, the Regional Fertility Centre at the Royal Victoria Hospital and the Urology Department at the Belfast City Hospital.
